Venus Remedies Ltd.

The present study was conducted to evaluate effect of sub-acute i.v. injection of ET_B receptor agonist IRL-1620 in mice.Swiss albino mice (n = 24, weighing 20-25 g) were divided into two groups (12 animal each), control group (0 μg kg^-1) and IRL-1620 treated group (1 μg/kg/min, i.v., for 30 days).Each group was further subdivided into two groups depending on sex of mice having 6 animals each.No significant change in animal body weight, hemogram, liver function test and renal function tests was observed on treatment with IRL-1620.Histol. examination of liver was normal and Kidneys showed mild congestion.In conclusion, sub-acute dose (1 μg/kg/min, i.v.) of endothelin receptor agonist ET_B IRL-1620 did not cause toxic effect on liver and kidney.

Osmotic agents are still the most common treatment options available for controlling intracranial pressure (ICP). Combining Mannitol and Glycerol provides a better alternative and is currently available as best therapy used for increased ICP. The aim of this work was to study the effects of repeated dosing (28 days) of Mannitol 20% and Glycerol 10% combined formulation, Neurotol plus on safety profile. A twenty eight days sub-acute toxicity study was conducted at three different dose levels of 5ml/kg, 10 ml/kg and 20 ml/kg. Mice were randomly divided into four groups of six animals each. Physical parameters, biochemical parameters related to liver toxicity & nephrotoxicity and hematological parameters were studied as end point of evaluation. We also carried out histopathlogical studies to assess any organ specific toxicity. The present study demonstrated that there were either no or very minimal changes (at high dose) were observed on various physical, biochemical and hematological parameters between Neurotol plus and control group. In conclusion the data of present study suggest that the combination of Mannitol and Glycerol is not associated with any serious adverse effects and is safe therapeutic choice for ICP reduction.

The present study investigated safety/toxicity profile of fixed dose combination of Ofloxacin-Ornidazole injection in Mus musculus mice at three dose levels, ranging from asymptomatic to high dose.To enhance the antimicrobial spectrum of the quinolones against anaerobic organisms and gram pos. bacteria, fixed dose combination of Ofloxacin and Ornidazole injection was introduced.It has been found highly effective as well as synergistic and has the potential of usage for empirical therapy because of extended spectrum.A 30 days repeat dose subchronic toxicity study was conducted on mice (male and female).Various physiol., hematol. and biochem. parameters were studied.There were no signs of toxicity observed at any dose level used in this study.No mortality was seen in any of the treatment groups.Hematol. as well as physiol. parameters were unaltered at three dose levels in Ofloxacin-Ornidazole treatment groups.Results suggest that the fixed dose combination of Ofloxacin-Ornidazole injection is non toxic even at maximum dose level.